Phase I Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

Researcher
Alexandra Zimmer, M.D., at the National Cancer Institute, Bethesda, MD
Study review

The purpose of this study was to investigate whether using Temodar and Kadcyla together decreases the chance of patients with HER2+ metastatic breast cancer developing new brain metastases.

The initial Call to Action for this study was on 9/19/2017 and the researchers closed enrollment on 6/14/2021. The Love Research Army provided them with 2 participants who were interested in enrolling in the study.